Elacestrant is an anticancer medication which is used in the treatment of breast cancer. Elacestrant was developed by Eisai Co Ltd and Menarini and Radius Health Inc. and Stemline Therapeutics.
The API has now reached off-patent status, after being launched in 2023.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Elacestrant and many others, contact info@pharmacheminvestor.com